Allstate Corp Buys 7,589 Shares of Boston Scientific Corporation $BSX

Key Points

• Allstate Corp increased its stake in Boston Scientific Corporation by 17.3%, acquiring an additional 7,589 shares, bringing its total holdings to 51,333 shares worth approximately $5.18 million.
• Multiple institutional investors, including Price T Rowe Associates and 1832 Asset Management, have also significantly raised their positions in Boston Scientific during the same quarter.
• Boston Scientific reported earnings that exceeded analyst expectations, with $0.75 earnings per share for the quarterly report, and updated its Q3 2025 guidance to between $0.700 and $0.720 EPS.

Allstate Corp raised its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,333 shares of the medical equipment provider's stock after buying an additional 7,589 shares during the quarter. Allstate Corp's holdings in Boston Scientific were worth $5,178,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of BSX. 1832 Asset Management L.P. increased its position in shares of Boston Scientific by 11.1% in the 1st quarter. 1832 Asset Management L.P. now owns 848,147 shares of the medical equipment provider's stock valued at $85,561,000 after buying an additional 84,585 shares in the last quarter. Compound Planning Inc. increased its stake in Boston Scientific by 9.0% during the 1st quarter. Compound Planning Inc. now owns 10,495 shares of the medical equipment provider's stock worth $1,059,000 after purchasing an additional 864 shares in the last quarter. Norinchukin Bank The raised its holdings in Boston Scientific by 15.1% during the 1st quarter. Norinchukin Bank The now owns 75,926 shares of the medical equipment provider's stock worth $7,659,000 after buying an additional 9,955 shares during the period. CW Advisors LLC boosted its holdings in shares of Boston Scientific by 2.5% in the first quarter. CW Advisors LLC now owns 241,289 shares of the medical equipment provider's stock valued at $24,344,000 after buying an additional 5,902 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in Boston Scientific by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the business's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,347,824.96. The trade was a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 over the last three months. Insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of several research reports. Truist Financial boosted their target price on Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Raymond James Financial boosted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Wells Fargo & Company upped their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. Finally, Oppenheimer upped their price target on shares of Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Stock Down 0.8%

Shares of BSX opened at $105.1650 on Friday. The stock has a fifty day moving average of $103.97 and a 200-day moving average of $102.14. Boston Scientific Corporation has a 52 week low of $78.53 and a 52 week high of $108.94. The stock has a market capitalization of $155.83 billion, a price-to-earnings ratio of 62.60, a PEG ratio of 2.55 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.